Nervous System News and Research

Latest Nervous System News and Research

Supernus SPN-812 Phase IIa U.S. clinical trial in ADHD meets primary endpoints

Supernus Pharmaceuticals, Inc. today announced that its Phase IIa U.S. clinical trial of SPN-812 in adults for the treatment of attention deficit hyperactivity disorder (ADHD) met the primary endpoints of safety and tolerability, and showed statistically significant median reduction versus placebo in both investigator-rated and patient-rated ADHD symptom scores.

11 Mar 2011

Arena fourth quarter net loss decreases to $28.2 million

Arena Pharmaceuticals, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2010, and reviewed recent developments.

11 Mar 2011

Scientific advances at Scripps Research lay foundation for new lupus drug Benlysta

Scientific advances at The Scripps Research Institute were key to laying the foundation for the new drug Benlysta® (belimumab), approved today by the U.S. Food and Drug Administration. Benlysta®, which treats the most common type of lupus, is the first in a new class of pharmaceuticals that prevents the body from attacking its own critical tissues.

11 Mar 2011

Neurogenesis plays a beneficial role in exercise-induced response to stress, sexual behavior and reproduction

Two studies published by an interdisciplinary team of Hong Kong researchers in the current special issue of Cell Transplantation (20:1), now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/ , link the regrowth of key adult brain cells (neurogenesis) in two critical areas of the brain to both the benefits of exercise as a stress reducer and also to sexual behavior and reproductive issues.

11 Mar 2011

SAMHSA study finds 51.5% drug-related hospital visits by older patients

Adults aged 50 and older comprise 51.5 percent of all emergency department visits each year related to adverse reactions to medications, according to a study by the Substance Abuse and Mental Health Services Administration.

11 Mar 2011

Researchers create protein molecule for new anti-inflammatory therapies

Researchers from across multiple disciplines at NYU Langone Medical Center created a new protein molecule derived from the growth factor progranulin may provide the basis for new therapies in inflammatory diseases, such as rheumatoid arthritis, according to a study published in the March 10, 2011 issue of Science.

11 Mar 2011

Novartis new MS treatment receives Notice of Compliance in Canada

Novartis Pharmaceuticals Canada Inc. announced today that its new MS treatment, Gilenya, has received Notice of Compliance in Canada.

10 Mar 2011

Positive results from exenatide phase 2 study in patients with type 2 diabetes

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced positive results from a phase 2 study evaluating the effects of a once-monthly injectable suspension formulation of exenatide on glycemic control in patients with type 2 diabetes.

10 Mar 2011

International panel revises, simplifies 'McDonald Criteria' for diagnosis of multiple sclerosis

International Panel Revises "McDonald Criteria" for Diagnosing MS -- Use of new data should speed diagnosis -- Publication coincides with MS Awareness Week

10 Mar 2011

Professor utilizes $300,000 N.Y. grant to study adult neural stem cells

Rensselaer Polytechnic Institute Assistant Professor of Biomedical Engineering Deanna Thompson is utilizing more than $300,000 in New York state funding as part of the state stem cell research program, NYSTEM, to study adult neural stem cells.

10 Mar 2011

CDH Proton Center expands treatment capacity

The CDH Proton Center, A ProCure Center, in suburban Chicago, is now able to treat a wider variety of cancer tumors with the opening of a treatment room with a gantry, a nearly 100-ton rotating steel wheel that allows the proton beam to be directed at the tumor from any angle.

10 Mar 2011

NextGen Group subsidiary completes commercial reorganization

NextGen Group plc is pleased to announce that its subsidiary NextGen Sciences Inc, a leader in biomarker discovery, measurement and qualification, has completed a commercial reorganization. The restructuring, which is accompanied by new management appointments, is expected to help the company execute its strategy of becoming a leading player in the growing oncology and central nervous system (CNS) biomarker markets.

10 Mar 2011

Study finds synapses between retinal ganglion cells and starburst amacrine cells distributed asymmetrically

The sensory cells in the retina of the mammalian eye convert light stimuli into electrical signals and transmit them via downstream interneurons to the retinal ganglion cells which, in turn, forward them to the brain. The interneurons are connected to each other in such a way that the individual ganglion cells receive visual information from a circular area of the visual field known as the receptive field.

10 Mar 2011

FDA approves BENLYSTA for active, autoantibody-positive systemic lupus erythematosus

Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced that the U.S. Food and Drug Administration has approved BENLYSTA® (belimumab) for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy.

10 Mar 2011

KineMed extends collaboration with BMY to identify and characterize Alzheimer's biomarkers

KineMed, Inc. announced today the extension of its collaboration with Bristol-Myers Squibb in the area of Alzheimer's disease and other neurodegenerative conditions.

9 Mar 2011

Human Genome Sciences receives FDA approval for Benlysta to treat lupus

The U.S. Food and Drug Administration today approved Benlysta to treat patients with active, autoantibody-positive lupus who are receiving standard therapy, including corticosteroids, antimalarials, immunosuppressives, and nonsteroidal anti-inflammatory drugs.

9 Mar 2011

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced that several new data analyses from Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be presented at The International Liver CongressTM / 46th European Association for the Study of the Liver annual meeting.

9 Mar 2011

Sanfilippo syndrome compromises blood-brain barrier, leads to brain damage

A study into the effects of Sanfilippo Syndrome type B (MPS III B) has found that the barrier responsible for protecting the brain from the entry of harmful blood-borne substances is structurally and functionally damaged by the devastating disease. University of South Florida researchers identified damage in specific brain structures involved in the pathology of MPS III B, one of four Sanfilippo syndromes, all of which are inherited diseases of metabolism.

9 Mar 2011

Therapeutic potential of iPS cells may be limited by reprogramming errors and genomic instability

In the past few months, a slew of papers have indicated that the therapeutic potential of a promising type of stem cell, called induced pluripotent stem (iPS) cells, might be limited by reprogramming errors and genomic instability. iPS cells are engineered by reprogramming fully differentiated adult cells, often skin cells, back to a primitive, embryonic-like state.

9 Mar 2011

Allergy Asthma Research Institute, Forest Labs join SAFE-BioPharma

In a move to improve efficiency by reducing paper in their respective operations, Forest Laboratories and the Allergy Asthma Research Institute have joined SAFE-BioPharma Association. They now have access to the SAFE-BioPharma® digital identity and signature standard, used throughout the biopharmaceutical industry to verify and manage digital identities involved in electronic transactions and to apply digital signatures to electronic documents.

9 Mar 2011

Nervous System News and Research

Latest Nervous System News and Research

Supernus SPN-812 Phase IIa U.S. clinical trial in ADHD meets primary endpoints

Arena fourth quarter net loss decreases to $28.2 million

Scientific advances at Scripps Research lay foundation for new lupus drug Benlysta

Neurogenesis plays a beneficial role in exercise-induced response to stress, sexual behavior and reproduction

SAMHSA study finds 51.5% drug-related hospital visits by older patients

Researchers create protein molecule for new anti-inflammatory therapies

Novartis new MS treatment receives Notice of Compliance in Canada

Positive results from exenatide phase 2 study in patients with type 2 diabetes

International panel revises, simplifies 'McDonald Criteria' for diagnosis of multiple sclerosis

Professor utilizes $300,000 N.Y. grant to study adult neural stem cells

CDH Proton Center expands treatment capacity

NextGen Group subsidiary completes commercial reorganization

Study finds synapses between retinal ganglion cells and starburst amacrine cells distributed asymmetrically

FDA approves BENLYSTA for active, autoantibody-positive systemic lupus erythematosus

KineMed extends collaboration with BMY to identify and characterize Alzheimer's biomarkers

Human Genome Sciences receives FDA approval for Benlysta to treat lupus

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Sanfilippo syndrome compromises blood-brain barrier, leads to brain damage

Therapeutic potential of iPS cells may be limited by reprogramming errors and genomic instability

Allergy Asthma Research Institute, Forest Labs join SAFE-BioPharma

Industry Focus eBook - Medical device (1st edition) eBook

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Nervous System News and Research

Latest Nervous System News and Research

Industry Focus eBook - Medical device (1st edition) eBook

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Newsletters you may be interested in